Non-invasive early-stage pancreatic cancer develops with mutations in KRAS, and these pancreatic cancer precursor lesions are thought to progress to invasive cancer through the inactivation of tumor suppressor genes such as TP53, SMAD4, and CDKN2A4, following the KRAS mutation [51]. This evidence concerns the gene KRAS and cancer.